Chronic administration of AM251 improves albuminuria and renal tubular structure in obese rats

Journal of Endocrinology

Volumn 225, Issue 2, 2015, Pages 113-124

  Jenkin, Kayte A ^a   O'Keefe, Lannie ^a   Simcocks, Anna C ^a   Grinfeld, Esther ^a   Mathai, Michael L ^a,b   McAinch, Andrew J ^a   Hryciw, Deanne H ^c  

^a VICTORIA UNIVERSITY   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cannabinoids; Kidney; Leptin; Obesity

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ALBUMIN; CANNABINOID 1 RECEPTOR; COLLAGEN TYPE 4; CREATININE; LEPTIN; MEGALIN; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA1; COLLAGEN; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TGFB1 PROTEIN, RAT; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DIET INDUCED OBESITY; DRUG ANTAGONISM; DRUG MECHANISM; HYPERLEPTINEMIA; IN VIVO STUDY; KIDNEY; LIPID DIET; LOW FAT DIET; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; SODIUM EXCRETION; SPRAGUE DAWLEY RAT; SYSTOLIC BLOOD PRESSURE; TUBULAR DYSFUNCTION; URINALYSIS; WEIGHT GAIN; ADVERSE EFFECTS; ANIMAL; GENETICS; HUMAN; KIDNEY TUBULE; METABOLISM; OBESITY; PATHOLOGY;

ALBUMINURIA; ANIMALS; COLLAGEN; DIET, HIGH-FAT; HUMANS; KIDNEY TUBULES; MALE; OBESITY; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84930792541     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-15-0004     Document Type: Article

References (68)

1. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J & de Boer IH 2013 Kidney disease and increased mortality risk in type 2 diabetes. Journal of the American Society of Nephrology 24 302-308. (doi:10.1681/ASN.2012070718)
2. Ahima RS & Flier JS 2000 Adipose tissue as an endocrine organ. Trends in Endocrinology and Metabolism 11 327-332. (doi:10.1016/S1043-2760(00)00301-5)
3. Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, Nakaoke R & Morley JE 2004 Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 53 1253-1260. (doi:10.2337/diabetes.53.5.1253)
4. Barutta F, Corbelli A, Mastrocola R, Gambino R, Di Marzo V, Pinach S, Rastaldi MP, Perin PC & Gruden G 2010 Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 59 1046-1054. (doi:10.2337/db09-1336)
5. Birn H & Christensen EI 2006 Renal albumin absorption in physiology and pathology. Kidney International 69 440-449. (doi:10.1038/sj.ki.5000141)
6. Briffa JF, McAinch AJ, Poronnik P & Hryciw DH 2013 Adipokines as a link between obesity and chronic kidney disease. American Journal of Physiology. Renal Physiology 305 F1629-F1636. (doi:10.1152/ajprenal.00263.2013)
7. Briffa JF, Grinfeld E, Mathai ML, Poronnik P, McAinch AJ & Hryciw DH 2014 Acute leptin exposure reduces megalin expression and upregulates TGFb1 in cultured renal proximal tubule cells. Molecular and Cellular Endocrinology 401 25-34. (doi:10.1016/j.mce.2014.11.024)
8. Cignarelli M & Lamacchia O 2007 Obesity and kidney disease. Nutrition, Metabolism, and Cardiovascular Diseases 17 757-762. (doi:10.1016/j.numecd.2007.03.003)
9. Daugherty A, Rateri D, Hong L & Balakrishnan A 2009 Measuring blood pressure in mice using volume pressure recording, a tail-cuff method. Journal of Visualized Experiments 27 1-2. (doi:10.3791/1291)
10. Deshpande LS, Blair RE, Ziobro JM, Sombati S, Martin BR & De Lorenzo RJ 2007 Endocannabinoids block status epilepticus in cultured hippocampal neurons. European Journal of Pharmacology 558 52-59. (doi:10.1016/j.ejphar.2006.11.030)
11. Despres JP, Golay A & Sjostrom L 2005 Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine 353 2121-2134. (doi:10.1056/NEJMoa044537)
12. Di Marzo V 2008 The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 51 1356-1367. (doi:10.1007/s00125-008-1048-2)
13. Dobrian AD, Davies MJ, Prewitt RL & Lauterio TJ 2000 Development of hypertension in a rat model of diet-induced obesity. Hypertension 35 1009-1015. (doi:10.1161/01. HYP.35.4.1009)
14. Gatley SJ, Gifford AN, Volkow ND, Lan R & Makriyannis A 1996 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. European Journal of Pharmacology 307 331-338. (doi:10.1016/0014-2999(96)00279-8)
15. Gekle M, Knaus P, Nielsen R, Mildenberger S, Freudinger R, Wohlfarth V, Sauvant C & Christensen EI 2003 Transforming growth factor-b1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells. Journal of Physiology 552 471-481. (doi:10.1113/jphysiol.2003.048074)
16. Gonzalez-Albarran O, Gomez O, Ruiz E, Vieitez P & Garcia-Robles R 2003 Role of systolic blood pressure on the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity, and hypertension (Zucker rats). American Journal of Hypertension 16 979-985. (doi:10.1016/S0895-7061(03)01000-8)
17. Griffin KA, Kramer H & Bidani AK 2008 Adverse renal consequences of obesity. American Journal of Physiology. Renal Physiology 294 F685-F696. (doi:10.1152/ajprenal.00324.2007)
18. Haller J, Varga B, Ledent C & Freund TF 2004 CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behavioural Pharmacology 15 299-304. (doi:10.1097/01.fbp.0000135704.56422.40)
19. Hama H, Saito A, Takeda T, Tanuma A, Xie Y, Sato K, Kazama JJ & Gejyo F 2004 Evidence indicating that renal tubular metabolism of leptin is mediated by megalin but not by the leptin receptors. Endocrinology 145 3935-3940. (doi:10.1210/en.2004-0074)
20. Henegar JR, Bigler SA, Henegar LK, Tyagi SC & Hall JE 2001 Functional and structural changes in the kidney in the early stages of obesity. Journal of the American Society of Nephrology 12 1211-1217.
21. Henstridge CM, Balenga NA, Schroder R, Kargl JK, Platzer W, Martini L, Arthur S, Penman J, Whistler JL, Kostenis E et al. 2010 GPR55 ligands promote receptor coupling to multiple signalling pathways. British Journal of Pharmacology 160 604-614. (doi:10.1111/j.1476-5381.2009.00625.x)
22. Hryciw DH, Jenkin KA, Simcocks AC, Grinfeld E, McAinch AJ & Poronnik P 2012 The interaction between megalin and ClC-5 is scaffolded by the Na(+)-H(+) exchanger regulatory factor 2 (NHERF2) in proximal tubule cells. International Journal of Biochemistry & Cell Biology 44 815-823. (doi:10.1016/j.biocel.2012.02.007)
23. Hsu YC, Lei CC, Shih YH, Ho C & Lin CL 2014 Induction of proteinuria by cannabinoid receptors 1 signaling activation in CB1 transgenic mice. American Journal of the Medical Sciences 349 162-168. (doi:10.1097/MAJ.0000000000000352)
24. Hughes J & Gobe G 2007 Identification and quantification of apoptosis in the kidney using morphology, biochemical and molecular markers. Nephrology 12 452-458. (doi:10.1111/j.1440-1797.2007.00854.x)
25. Ishibashi F 2004 High glucose reduces albumin uptake in cultured proximal tubular cells (LLC-PK1). Diabetes Research and Clinical Practice 65 217-225. (doi:10.1016/j.diabres.2004.02.003)
26. Janiak P, Poirier B, Bidouard JP, Cadrouvele C, Pierre F, Gouraud L, Barbosa I, Dedio J, Maffrand JP, Le Fur G et al. 2007 Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney International 72 1345-1357. (doi:10.1038/sj.ki.5002540)
27. Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, Egan GF, McKinley MJ, Rodger PD, Sinclair AJ et al. 2008 Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. PNAS 105 6531-6536. (doi:10.1073/pnas.0802690105)
28. Jenkin KA, McAinch AJ, Grinfeld E & Hryciw DH 2010 Role for cannabinoid receptors in human proximal tubular hypertrophy. Cellular Physiology and Biochemistry 26 879-886. (doi:10.1159/000323997)
29. Jenkin KA, Verty AN, McAinch AJ & Hryciw DH 2012 Endocannabinoids and the renal proximal tubule: an emerging role in diabetic nephropathy. International Journal of Biochemistry & Cell Biology 44 2028-2031. (doi:10.1016/j.biocel.2012.07.008)
30. Jenkin KA, McAinch AJ, Briffa JF, Zhang Y, Kelly DJ, Pollock CA, Poronnik P & Hryciw DH 2013 Cannabinoid receptor 2 expression in human proximal tubule cells is regulated by albumin independent of ERK1/2 signaling. Cellular Physiology and Biochemistry 32 1309-1319. (doi:10.1159/000354529)
31. Jenkin KA, O'Keefe L, Simcocks AC, Briffa JF, Mathai ML, McAinch AJ & Hryciw DH 2015a Renal effects of chronic pharmacologicalmanipulation of CB2 in rats with diet induced obesity. British Journal of Pharmacology [in press]. (doi:10.1111/bph.13056)
32. Jenkin KA, McAinch AJ, Zhang Y, Kelly DJ & Hryciw DH 2015b Elevated CB1 and GPR55 receptor expression in proximal tubule cells and whole kidney exposed to diabetic conditions. Clinical and Experimental Pharmacology & Physiology 42 256-262. (doi:10.1111/1440-1681.12355)
33. Jiang T, Wang Z, Proctor G, Moskowitz S, Liebman SE, Rogers T, Lucia MS, Li J & Levi M 2005 Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. Journal of Biological Chemistry 280 32317-32325. (doi:10.1074/jbc. M500801200)
34. Jonassen JA, San Agustin J, Follit JA & Pazour GJ 2008 Deletion of IFT20 in the mouse kidney causes misorientation of the mitotic spindle and cystic kidney disease. Journal of Cell Biology 183 377-384. (doi:10.1083/jcb.200808137)
35. Judge MK, Zhang Y & Scarpace PJ 2009 Responses to the cannabinoid receptor-1 antagonist, AM251, are more robust with age and with high-fat feeding. Journal of Endocrinology 203 281-290. (doi:10.1677/JOE-09-0210)
36. Kahn SE, Hull RL & Utzschneider KM 2006 Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444 840-846. (doi:10.1038/nature05482)
37. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS & Abood ME 2009 Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. Journal of Biological Chemistry 284 29817-29827. (doi:10.1074/jbc. M109.050187)
38. Keenan KP, Coleman JB, McCoy CL, Hoe CM, Soper KA & Laroque P 2000 Chronic nephropathy in ad libitum overfed Sprague-Dawley rats and its early attenuation by increasing degrees of dietary (caloric) restriction to control growth. Toxicologic Pathology 28 788-798. (doi:10.1177/019262330002800604)
39. Kramer H, Luke A, Bidani A, Cao G, Cooper R & McGee D 2005 Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. American Journal of Kidney Diseases 46 587-594. (doi:10.1053/j.ajkd.2005.06.007)
40. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R & Makriyannis A 1999 Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. Journal of Medicinal Chemistry 42 769-776. (doi:10.1021/jm980363y)
41. Le Floch JP, Escuyer P, Baudin E, Baudon D & Perlemuter L 1990 Blood glucose area under the curve. Methodological aspects. Diabetes Care 13 172-175. (doi:10.2337/diacare.13.2.172)
42. Lim AK, Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA & Tesch GH 2009 Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 52 1669-1679. (doi:10.1007/s00125-009-1399-3)
43. Lim JC, Lim SK, Han HJ & Park SH 2010 Cannabinoid receptor 1 mediates palmitic acid-induced apoptosis via endoplasmic reticulum stress in human renal proximal tubular cells. Journal of Cellular Physiology 225 654-663. (doi:10.1002/jcp.22255)
44. Litvin Y, Phan A, Hill MN, Pfaff DW & McEwen BS 2013 CB1 receptor signaling regulates social anxiety and memory. Genes, Brain, and Behavior 12 479-489. (doi:10.1111/gbb.12045)
45. Mathew AV, Okada S & Sharma K 2011 Obesity related kidney disease. Current Diabetes Reviews 7 41-49. (doi:10.2174/157339911794273928)
46. Merroun I, Sanchez-Gonzalez C, Martinez R, Lopez-Chaves C, Porres JM, Aranda P, Llopis J, Galisteo M, Zarzuelo A, Errami M et al. 2013 Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats. Metabolism: Clinical and Experimental 62 1641-1650. (doi:10.1016/j.metabol.2013.06.011)
47. Mingorance C, Alvarez de Sotomayor M, Jimenez-Palacios FJ, Callejon Mochon M, Casto C, Marhuenda E & Herrera MD 2009 Effects of chronic treatment with the CB1 antagonist, rimonabant on the blood pressure, and vascular reactivity of obese Zucker rats. Obesity 17 1340-1347. (doi:10.1038/oby.2009.20)
48. Nam DH, Lee MH, Kim JE, Song HK, Kang YS, Lee JE, Kim HW, Cha JJ, Hyun YY, Kim SH et al. 2012 Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Endocrinology 153 1387-1396. (doi:10.1210/en.2011-1423)
49. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, Biryukov S, Abbafati C, Abera SF et al. 2014 Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 766-781. (doi:10.1016/S0140-6736(14)60460-8)
50. Nolan E, O'Meara YM & Godson C 2013 Lipid mediators of inflammation in obesity-related glomerulopathy. Nephrology, Dialysis, Transplantation 28 iv22-iv29. (doi:10.1093/ndt/gft392)
51. De Oliveira Alvares L, Genro BP, Vaz Breda R, Pedroso MF, Da Costa JC & Quillfeldt JA 2006 AM251, a selective antagonist of the CB1 receptor, inhibits the induction of long-term potentiation and induces retrograde amnesia in rats. Brain Research 1075 60-67. (doi:10.1016/j.brainres.2005.11.101)
52. Pacher P, Batkai S & Kunos G 2005 Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology 48 1130-1138. (doi:10.1016/j.neuropharm.2004.12.005)
53. Rosenstock J, Hollander P, Chevalier S & Iranmanesh A 2008 SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 31 2169-2176. (doi:10.2337/dc08-0386)
54. Russo LM, del Re E, Brown D & Lin HY 2007 Evidence for a role of transforming growth factor (TGF)-α1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-b type II receptor. Diabetes 56 380-388. (doi:10.2337/db06-1018)
55. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T & Greasley PJ 2007 The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology 152 1092-1101. (doi:10.1038/sj.bjp.0707460)
56. Shearman LP, Rosko KM, Fleischer R, Wang J, Xu S, Tong XS & Rocha BA 2003 Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behavioural Pharmacology 14 573-582. (doi:10.1097/00008877-200312000-00001)
57. Sink KS, McLaughlin PJ, Wood JA, Brown C, Fan P, Vemuri VK, Peng Y, Olszewska T, Thakur GA, Makriyannis Aet al. 2008 Thenovel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33 946-955. (doi:10.1038/sj.npp.1301476)
58. Slattery C, Jenkin KA, Lee A, Simcocks AC, McAinch AJ, Poronnik P & Hryciw DH 2011 Na+-H+ exchanger regulatory factor 1 (NHERF1) PDZ scaffold binds an internal binding site in the scavenger receptor megalin. Cellular Physiology and Biochemistry 27 171-178. (doi:10.1159/000325219)
59. Slattery C, Jang Y, Kruger WA, Hryciw DH, Lee A & Poronnik P 2013 g-Secretase inhibition promotes fibrotic effects of albumin in proximal tubular epithelial cells. British Journal of Pharmacology 169 1239-1251. (doi:10.1111/bph.12214)
60. Son MH, Kim HD, Chae YN, Kim MK, Shin CY, Ahn GJ, Choi SH, Yang EK, Park KJ, Chae HW et al. 2010 Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. International Journal of Obesity 34 547-556. (doi:10.1038/ijo.2009.253)
61. Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, Szanda G, Mukhopadhyay B, Chedester L, Liow JS et al. 2012 Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metabolism 16 167-179. (doi:10.1016/j.cmet.2012.07.002)
62. Toffaletti JG & McDonnell EH 2008 Variation of serum creatinine, cystatin C, and creatinine clearance tests in persons with normal renal function. Clinica Chimica Acta 395 115-119. (doi:10.1016/j.cca.2008.05.020)
63. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O & Rossner S 2005 Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 1389-1397. (doi:10.1016/S0140-6736(05)66374-X)
64. Wang Y, Chen X, Song Y, Caballero B & Cheskin LJ 2008 Association between obesity and kidney disease: a systematic review and metaanalysis. Kidney International 73 19-33. (doi:10.1038/sj.ki.5002586)
65. Wohlfarth V, Drumm K, Mildenberger S, Freudinger R & Gekle M 2003 Protein uptake disturbs collagen homeostasis in proximal tubulederived cells. Kidney International. Supplement 63 S103-S109. (doi:10.1046/j.1523-1755.63.s84.13.x)
66. Wolf G & Ziyadeh FN 1999 Molecular mechanisms of diabetic renal hypertrophy. Kidney International 56 393-405. (doi:10.1046/j.1523-1755.1999.00590.x)
67. Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang Y, Yang D, Liang H, Ye J & Weng J 2011 Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS ONE 6 e16556. (doi:10.1371/journal.pone.0016556)
68. Zhang X, Li ZL, Woollard JR, Eirin A, Ebrahimi B, Crane JA, Zhu XY, Pawar AS, Krier JD, Jordan KL et al. 2013 Obesity-metabolic derangement preserves hemodynamics but promotes intrarenal adiposity and macrophage infiltration in swine renovascular disease. American Journal of Physiology. Renal Physiology 305 F265-F276. (doi:10.1152/ajprenal.00043.2013)